Mirimus, Inc.
NY Doing business as Mirimus Inc.
- UEI
- CP76MKEFKFE4
- CAGE
- 6DUZ3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Mirimus, Inc.
CP76MKEFKFE4
- Micoy Therapeutics, Inc. M3E7XWR3SN95
-
Mirimus, Inc.
CP76MKEFKFE4
- SAM.gov registration date
- Physical address
- 760 Parkside Ave #206, Brooklyn, NY 11226, USA
- Website
- mirimus.com
- Founded
- 2010
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Creation of the next generation rnai therapeutics and an in vivo model for their study - abstract RNA interference… | National Institute of General Medical Sciences | $700,000 | |
| Breeding and genotype service | NIH Clinical Center | $21,450 | |
| Preclinical evaluation of a novel ADAM10 modulator to treat colorectalcancer - abstract colorectal cancer (CRC) is the… | National Cancer Institute | $397,916 | |
| Reagents needed for research. | NIH Clinical Center | $17,985 | |
| Radx tech II: saliva pool testing for high throughput detection and variant identification | National Heart Lung and Blood Institute | $1,167,000 |
About Mirimus, Inc.
Mirimus, Inc. is a corporate entity registered in SAM.gov since 2011, classified as a self-certified small disadvantaged business located in Brooklyn, NY. The company specializes in scientific research services, particularly in the areas of biological research, genetic engineering, and advanced therapeutic development. Mirimus demonstrates expertise in providing scientific supplies, reagents, testing services, and innovative research solutions to various federal agencies, with a strong focus on biomedical and medical research technologies.
Through federal contract awards, Mirimus has primarily worked with the National Institutes of Health (NIH), specifically the NIH Clinical Center and the National Heart, Lung and Blood Institute. The company has secured contracts for breeding and genotype services, scientific supplies, and specialized testing services. A notable contract was a $1.167 million firm fixed price award for saliva pool testing services in support of coronavirus monitoring efforts, specifically the RADX TECH II project for high-throughput detection and variant identification. These contracts have ranged in value from approximately $15,000 to $1.17 million, with contract types including purchase orders and definitive contracts, and all awards were made without specific set-aside designations.
Mirimus has received federal grant awards focused on advanced therapeutic research, particularly in RNA interference (RNAi) technologies and cancer research. The company was awarded a $700,000 grant from the National Institute of General Medical Sciences to develop next-generation RNAi therapeutics and create an in vivo model for evaluating their efficacy and biodistribution. Another significant grant of unspecified amount was received from the National Cancer Institute to support preclinical evaluation of a novel ADAM10 modulator for treating colorectal cancer. These grants aim to accelerate the development of innovative biological drug candidates, with a focus on creating sophisticated research models and exploring targeted therapeutic approaches for complex medical conditions.
Quick answers
What is Mirimus, Inc.'s UEI?
Mirimus, Inc.'s Unique Entity ID (UEI) in SAM.gov is CP76MKEFKFE4.
What is Mirimus, Inc.'s CAGE code?
Mirimus, Inc.'s CAGE code is 6DUZ3.
What is Mirimus, Inc.'s primary NAICS code?
Mirimus, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Mirimus, Inc. located?
Mirimus, Inc.'s physical address in SAM.gov is 760 Parkside Ave #206, Brooklyn, NY 11226, USA.
Is Mirimus, Inc. registered in SAM.gov?
Yes. Mirimus, Inc.'s SAM.gov registration is active through January 13, 2027.
What is Mirimus, Inc.'s most recent federal award?
Mirimus, Inc.'s most recent federal grant award is Creation of the next generation rnai therapeutics and an in vivo model for their study - abstract RNA interference… (R43GM154496), from National Institute of General Medical Sciences, on September 20, 2024.
On GovTribe
See Mirimus, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors